This 2018 review by Salzano et al. explores the therapeutic potential of growth hormone (GH) replacement in patients with chronic heart failure (CHF), a condition often associated with acquired GH deficiency. The authors outline how GH and its mediator IGF-1 influence myocardial function, vascular tone, and metabolic regulation. Although animal
This review examines the therapeutic potential of growth hormone-releasing hormone (GHRH) analogs, including both agonists and antagonists, in various medical fields such as oncology, regenerative medicine, and metabolic disorders. GHRH agonists have shown promise in promoting tissue regeneration, improving cardiac function, and enhancing islet survival in diabetes, while GHRH antagonists
This systematic review assessed the effects of hawthorn extract as an adjunctive treatment for chronic heart failure (CHF), analyzing data from 14 randomized, double-blind, placebo-controlled trials involving 855 patients. The findings showed that hawthorn extract significantly improved exercise tolerance, increased maximal workload, reduced the pressure-heart rate product, and alleviated symptoms
This position paper from the International Lipid Expert Panel (ILEP), published in Nutrition Research Reviews (PMID: 32172721), evaluates the clinical evidence supporting the use of nutraceuticals in managing heart failure (HF). It highlights supplements such as coenzyme Q10, L-carnitine, omega-3 fatty acids, probiotics, beet nitrates, D-ribose, carnosine, hawthorn, and vitamin
The review article examines the role of Coenzyme Q10 (CoQ10) in the management of chronic heart failure (HF), emphasizing its biochemical function in mitochondrial energy production and antioxidant activity. The Q-SYMBIO trial demonstrated that CoQ10 supplementation significantly reduced cardiovascular mortality by 42% (p=0.026) and all-cause mortality by 43% (p=0.036) over
This review explores the development and potential therapeutic applications of thyroid hormone analogs, which are designed to replicate the beneficial effects of thyroid hormones—such as enhanced cardiac function, weight loss, and reduced serum cholesterol—while minimizing adverse effects on the heart, bone, and skeletal muscle. These analogs have been studied for
A randomized, double-blind, placebo-controlled trial examined the cardiometabolic effects of combined levothyroxine (LT4) and liothyronine (LT3) therapy versus LT4 alone in athyreotic patients without cardiovascular risk factors. The study included 38 patients with postsurgical hypothyroidism, of whom 24 completed one year of treatment. The LT4+LT3 group demonstrated a significant improvement
The randomized controlled trial titled “A randomized trial comparing triiodothyronine (T3) with thyroxine (T4) for hemodynamically unstable brain-dead organ donors” (Clinical Transplantation, 2019, PMID: 30689222) investigated the effects of T3 versus T4 hormone therapy on hemodynamic stability in brain-dead organ donors. The study found that T3 therapy improved cardiac function
